Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
NCT06249308 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 168
Last updated 2024-02-08
Summary
This study is a multi-center, observational study aiming at developing a machine learning-based early detection model using prospectively collected liquid biopsy samples from newly diagnosed ovarian cancer.
Conditions
Interventions
- OTHER
-
Blood collection
Blood sample will be collected
Sponsors & Collaborators
-
Shanghai Weihe Medical Laboratory Co., Ltd.
collaborator INDUSTRY -
Fudan University
lead OTHER
Principal Investigators
-
Hao Wen, M.D., Ph.D. · Fudan University
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-18
- Primary Completion
- 2025-12-31
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Transforming Ovarian Cancer Diagnostic Pathways
NCT06129968 ·Status: RECRUITING
-
Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer
NCT06640348 ·Status: RECRUITING
-
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
NCT05976932 ·Status: UNKNOWN
-
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer
NCT06709872 ·Status: RECRUITING
-
Screening Women at High Genetic Risk for Ovarian Cancer
NCT00033488 ·Status: COMPLETED ·Phase: NA
-
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
NCT00238342 ·Status: UNKNOWN ·Phase: NA
-
Ovarian Screening Study
NCT00267072 ·Status: COMPLETED
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN
-
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
NCT01292733 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425 ·Status: ACTIVE_NOT_RECRUITING
-
Ovarian Tumor Biopsies to Study Response to Treatments
NCT02952521 ·Status: COMPLETED
-
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923 ·Status: RECRUITING
-
PRO for Fighting FT in Ovarian Cancer
NCT06032975 ·Status: RECRUITING
-
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
NCT01074398 ·Status: UNKNOWN
-
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
NCT01696994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence
NCT06237946 ·Status: NOT_YET_RECRUITING
-
The Culture of Ovarian Cancer Organoids and Drug Screening
NCT04768270 ·Status: UNKNOWN
-
To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
NCT06315270 ·Status: NOT_YET_RECRUITING
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test
NCT06445621 ·Status: RECRUITING
-
Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer
NCT04971421 ·Status: UNKNOWN
-
CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women
NCT00058032 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer
NCT05410015 ·Status: RECRUITING
-
O-RADS MRI System on Early Detection of Ovarian Cancer
NCT07009743 ·Status: ACTIVE_NOT_RECRUITING
-
Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma
NCT03302884 ·Status: UNKNOWN ·Phase: NA